“It is true that some off-label drug use is based on very unsettled science and has more risks. But medicine - and not just cancer care - involves lots of hard choices. And the more serious the disorder, often the more likely it is that for every right and wrong treatment choice there are many other practical decisions painted in shades of gray.”

American physician and investor

Scott Gottlieb is an American physician and investor. He served as the 23rd commissioner of the U.S. Food and Drug Administration from 2017 to 2019, and he is a contributor to CNBC and CBS News’ Face the Nation. He is a senior fellow at the American Enterprise Institute, a partner at New Enterprise Associates, and a board member at Pfizer, UnitedHealth Group, and Illumina. He is also an elected member of the National Academy of Medicine and the author of Uncontrolled Spread, a New York Times bestselling book about the COVID-19 pandemic and the national security weaknesses it exposed.